Ketogenic diet shows feasibility in women with endometrial cancer

The biggest takeaway from this endometrial cancer study is not a miracle claim. It is that a very low-carbohydrate ketogenic diet was actually workable, measurable and metabolically active in treatment-naïve women who were overweight or obese, the exact kind of population where obesity and insulin resistance are part of the disease picture.

Published May 27, 2026 in Nature Communications, the randomized feasibility trial compared a standard diet with a ketogenic approach in women with endometrial cancer. The paper, led by Ezequiel Dantas, Katie C. Hootman and Jennifer Moyer, did not try to sell keto as a cure. It asked a narrower, more useful question: can this kind of diet be delivered safely and realistically in a cancer setting, and does it produce the expected biologic shift? On that front, the answer was yes. Women on the ketogenic intervention showed rising serum ketones and falling insulin and glucose, the classic signs of nutritional ketosis. The team also used imaging and molecular methods to look for changes in tumor behavior and biomarker expression, keeping the focus on whether diet could alter the environment around the cancer, not just the scale.

That framing matters because endometrial cancer is one of the most common gynecologic cancers, and excess weight is tightly linked to risk. In other words, this is not keto drifting into wellness-advice territory. It is keto being tested as a structured medical nutrition intervention in a disease where metabolism matters. The study’s real strength is that it looked beyond short-term weight loss and into feasibility, adherence and tolerability, the stuff that decides whether a trial can move from promising idea to something worth scaling.

This paper also fits into a longer line of work. In 2018, a randomized trial at the University of Alabama at Birmingham followed 45 overweight or obese women with ovarian or endometrial cancer and found that 12 weeks on a ketogenic diet produced lower body fat and fasting insulin than a low-fat American Cancer Society diet. Memorial Sloan Kettering later described a pilot study in newly diagnosed endometrial cancer patients that tested whether they could tolerate keto for three to four weeks before surgery and whether it might stabilize insulin and blood sugar while affecting the tumor itself. The National Cancer Institute trial description went even further, saying a ketogenic diet may lower inflammation, cholesterol, insulin and blood sugar in overweight or obese patients with stage I-IVB endometrial cancer.

That is where the story lands: not on a headline about keto curing cancer, but on a more grounded result that matters to anyone following this space. The diet did what it was supposed to do biologically, and it did so in a group where that signal is worth watching.